Princeton, NJ (PRWEB UK) 20 May 2011
• Results from Second Phase 3 Study of YERVOY™ (ipilimumab) in Patients with Metastatic Melanoma Selected for ASCO Plenary Session
- Investigational Uses of Currently-Approved Products and Investigational Compounds to be Featured in More than 95 Abstracts
- Data Spans Broad Range of Therapeutic Approaches and More Than 15 Tumor Types
Bristol-Myers Squibb Company (NYSE:BMY), a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7. In a separate release, the company also announced that YERVOY™ (ipilimumab) received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in Europe for the treatment of patients with previously-treated unresectable or metastatic melanoma.
New data from YERVOY, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody, will be highlighted at the meeting, including:
- Results from a second Phase 3 study of YERVOY in patients with metastatic melanoma, which have been selected for presentation in the plenary session at ASCO on Sunday, June 5.
- Survival and safety data from a separate study investigating YERVOY in metastatic melanoma patients with stable asymptomatic brain metastases.
- Data from a clinical trial describing the response to YERVOY in patients with metastatic melanoma according to their baseline BRAF status.
“The presentations at ASCO reflect our broad commitment to oncology and, specifically, the science of immuno-oncology, a key area of research at Bristol-Myers Squibb that focuses on leveraging the potential of the immune system’s intrinsic ability to fight cancer,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. “With the recent FDA approval of YERVOY, today’s CHMP positive opinion and additional clinical trial results, our R&D group is gaining momentum in the exploration of our various compounds’ potential in a broad range of cancers.”
Other Key Oncology Asset News
Bristol-Myers Squibb and its partner, Abbott, will present updated Phase 1 and 2 results on elotuzumab, which is under development for the treatment of multiple myeloma. Elotuzumab is an investigational humanized monoclonal antibody specifically targeted against CS1, a cell-surface glycoprotein that is highly and uniformly expressed on multiple myeloma cells. On Sunday, June 5, updated results evaluating the safety and efficacy of elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma will be presented during an oral session. A Phase 3 clinical trial for elotuzumab in relapsed multiple myeloma was recently initiated and is now actively recruiting patients.
Separately, the company and its partner, Otsuka Pharmaceutical Co., Ltd., will present two-year follow up data from the Phase 3 head-to-head trial known as DASISION evaluating SPRYCEL® (dasatinib) vs. Gleevec®* (imatinib mesylate) in the treatment of patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic-phase. Five-year data from the Phase 3 study (-034) that evaluated the safety and efficacy of SPRYCEL in the treatment of Ph+ CML patients with resistance or intolerance to Gleevec will also be presented. Both sets of results will be presented on Friday, June 3.
ERBITUX ® (cetuximab) will be highlighted in abstracts that span a wide range of investigational uses in solid tumors such as colorectal, lung and head and neck. On Saturday, June 4, ERBITUX data evaluating the influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer will be featured in an oral presentation. Bristol-Myers Squibb is developing ERBITUX in partnership with Lilly.
IXEMPRA® (ixabepilone) will be featured in abstracts reporting results in combination regimens with other chemotherapies or targeted agents in different stages of breast cancer and results in different subgroups.
Other investigational compounds from the Bristol-Myers Squibb oncology portfolio will be presented, including Phase 2 advanced solid tumor data on brivanib, a selective dual inhibitor of FGF and VEGF signaling. On Monday, June 6, Phase 2 brivanib data in advanced soft tissue sarcoma will also be presented. BMS 754807 (a dual IGF-1R/IR inhibitor) and BMS 833293 (an SMO antagonist) will also be featured at ASCO.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the investigational compounds described in this release will receive regulatory approvals or, if approved, that they will become commercially successful. There is also no guarantee that the investigational uses of currently-approved products described in this release will lead to additional approved indications for such products. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2010, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
- Gleevec® is a registered trademark of Novartis AG
Media: Elzbieta Zawislak, +33615523580, elzbieta.zawislak(at)bms(dot)com
Investors: John Elicker, 609-252-4611, john.elicker(at)bms(dot)com
# # #